<DOC>
	<DOCNO>NCT02096861</DOCNO>
	<brief_summary>This study assess noninferiority efficacy ass overall safety CT P13 compare Remicade patient active Crohn 's disease Week 54 .</brief_summary>
	<brief_title>Demonstrate Noninferiority Efficacy Assess Safety CT-P13 Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female patient active Crohn 's disease Crohn 's disease activity index score 220 450 point Patient previously receive biological agent treatment Crohn 's disease . Patient allergy excipients infliximab , murine and/or human protein , patient hypersensitivity immunoglobulin product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>